Stock Fundamentals

Company Information

▼
Company Name
NRX Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US6294442099
CIK: 0001719406
CUSIP: 629444100
Currency: USD
Full Time Employees: 0
Phone: 484 254 6134
Website: https://www.nrxpharma.com
Fiscal Year End: December
IPO Date: Dec 04, 2017
Description:

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

Address:

1201 Orange Street, Wilmington, DE, United States, 19801

Directors & Officers

▼
Name Title Year Born
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chief Scientist Officer, Chairman & Interim CEO 1957
Mr. Michael S. Abrams Chief Financial Officer 1970
Mr. Joseph M. Casper Chief Operating Officer 1951
Dr. Riccardo Panicucci Ph.D. Chief Manufacturing & Technology Officer 1962
Suzanne Messere Investor Relations NA
Dr. Philip T. Lavin Ph.D. Chief Methodologist 1947

Institutional Holders

▼
Holder Name Shares Date Reported % Out Value % Change
Anson Funds Management LP 3.04M Dec 31, 2025 9.55% $0.78 50.31%
Vanguard Group Inc 729.84K Dec 31, 2025 2.29% $0.00 36.43%
AdvisorShares Investments, LLC 342.14K Sep 30, 2025 1.07% $0.18 29.70%
Marshall Wace Asset Management Ltd 189.14K Sep 30, 2025 0.59% $0.00 466.55%
Geode Capital Management, LLC 185.86K Sep 30, 2025 0.58% $0.00 7.90%
UBS Group AG 152.85K Sep 30, 2025 0.48% $0.00 25.69%
State Street Corp 76.28K Sep 30, 2025 0.24% $0.00 49.33%
Jane Street Group LLC 73.40K Sep 30, 2025 0.23% $0.00 0.00%
BlackRock Inc 65.41K Sep 30, 2025 0.21% $0.00 1.57%
Chicago Partners Investment Group LLC 41.99K Sep 30, 2025 0.13% $0.00 0.00%
One Wealth Management Investment & Advisory Services LLC 37.87K Dec 31, 2025 0.12% $0.11 35.30%
Northern Trust Corp 28.60K Sep 30, 2025 0.09% $0.00 0.00%
Two Sigma Investments LLC 17.44K Dec 31, 2025 0.05% $0.00 -66.68%
Ethos Financial Group LLC 11.90K Dec 31, 2025 0.04% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 11.08K Sep 30, 2025 0.03% $0.00 152.05%
Bank of America Corp 3.40K Sep 30, 2025 0.01% $0.00 -3.52%
SBI Securities Co Ltd 2.50K Sep 30, 2025 0.01% $0.00 -26.30%
Wells Fargo & Co 2.00K Sep 30, 2025 0.01% $0.00 0.00%
Advisor Group Holdings, Inc. 1.09K Sep 30, 2025 0.00% $0.00 1,111.11%
Tower Research Capital LLC 324.00 Sep 30, 2025 0.00% $0.00 -71.97%

Shares Statistics

▼
Shares Outstanding: 29.61M
Shares Float: 20.35M
% Insiders: 861.60%
% Institutions: 2,610.50%
Short % Float: 9.66%

🏆 Top 10 Institutional Holders

▼
Rank Holder Name Shares Held % of Shares Change Date Reported
1 Anson Funds Management LP 3.04M 9.55% ▲ 50.31% Dec 31, 2025
2 Vanguard Group Inc 729.84K 2.29% ▲ 36.43% Dec 31, 2025
3 AdvisorShares Investments, LLC 342.14K 1.07% ▲ 29.70% Sep 30, 2025
4 Marshall Wace Asset Management Ltd 189.14K 0.59% ▲ 466.55% Sep 30, 2025
5 Geode Capital Management, LLC 185.86K 0.58% ▲ 7.90% Sep 30, 2025
6 UBS Group AG 152.85K 0.48% ▲ 25.69% Sep 30, 2025
7 State Street Corp 76.28K 0.24% ▲ 49.33% Sep 30, 2025
8 Jane Street Group LLC 73.40K 0.23% ▲ 0.00% Sep 30, 2025
9 BlackRock Inc 65.41K 0.21% ▲ 1.57% Sep 30, 2025
10 Chicago Partners Investment Group LLC 41.99K 0.13% ▲ 0.00% Sep 30, 2025

Valuation Metrics

▼
Enterprise Value: $58.14M
Trailing P/E: 0.00
Forward P/E: 1.51

Financial Highlights

▼
Market Cap: $55.07M
EBITDA: $-15.20M
Book Value: $-0.93
Earnings/Share: $-2.31
Profit Margin: 0.00%
Operating Margin: -1,701.65%
ROA (TTM): -97.83%
ROE (TTM): -682.61%
Revenue (TTM): $242.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios (Yearly)

▼

Financial Ratios (Quarterly)

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 0.15x -0.28x 7.36x -18.26x -0.27x
2023-12-31 0.36x -0.78x 2.60x -229.89x -0.31x
2022-12-31 1.66x 1.42x 0.71x -9.68x -0.26x
2021-12-31 2.74x 0.02x 0.36x -5,288.94x -0.01x
2020-12-31 0.06x -0.07x 15.88x -393.95x -0.06x
2019-12-31 0.11x 0.07x 0.08x N/A 3.96x
2018-12-31 0.05x 0.01x 0.02x N/A 8.37x
2017-12-31 5.76x 0.00x 0.00x N/A 0.00x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 17, 2024 Jonathan C Javitt N/A Purchase 40.00K $1.17 $46.80K
Aug 30, 2023 Aaron Gorovitz N/A Purchase 3.50K $3.20 $11.20K
Aug 22, 2023 Jonathan C Javitt N/A Purchase 20.00K $3.20 $64.00K

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NRXP.US!